» Articles » PMID: 10948768

Corticosteroid-induced Osteoporosis: Pathogenesis and Prevention

Overview
Specialty Rheumatology
Date 2000 Aug 19
PMID 10948768
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In spite of their adverse side effects, natural and synthetic glucocorticoids (GCs) occupy a unique role in several fields of medicine. They are potent regulators of bone cell growth and differentiation and the actions on the skeleton and related tissues depend on several factors including the dose, duration of the exposure, the steroid type and the species. In humans some of the effects are indirect, such as the regulation of intestinal calcium absorption and PTH secretion. Other effects are due to the cellular response that occurs within the bone microenvironment. It has been well established in in vitro studies that GCs can promote osteoblast differentiation from mesenchymal osteoprogenitors both in rat calvarial culture and in adherent marrow stromal cells. Moreover, GCs are able to enhance expression of the mature osteoblast phenotype, increasing mineralized nodules, osteocalcin secretion, and the bone morphogenetic protein-6 message level. However, the mechanisms by which GCs affect bone metabolism are still unclear. Recent studies with GCs on bone cells suggested that the production of cytokines and growth factors and the expression of their receptors may also be influenced by GCs. In fact, GCs are able to inhibit the synthesis of cytokines, such as interleukin-1 which stimulates bone remodeling by monocytes and macrophages. Moreover, osteoprotegerin, a recently cloned member of the tumor necrosis factor receptor family, is down-regulated by GCs, offering a possible interpretation for the induction of bone resorption by GCs. GC-induced inhibition of bone resorbing cytokines may contribute to explain the therapeutic actions of GCs in several diseases such as rheumatoid arthritis and myeloma. Furthermore, GCs modulate osteoclast recruitment, even if there is no clear explanation for a direct effect of GCs on osteoclastic precursors. Sustained stimulation of matrix degradation by isolated avian osteoclasts incubated with GCs has been reported, as well as cytotoxic effects on osteoclastic cells from neonatal rat long bones.

Citing Articles

Hp-s1 Ganglioside Suppresses Proinflammatory Responses by Inhibiting MyD88-Dependent NF-κB and JNK/p38 MAPK Pathways in Lipopolysaccharide-Stimulated Microglial Cells.

Shih J, Tsai Y, Li I, Chen M, Huang Y Mar Drugs. 2020; 18(10).

PMID: 33003399 PMC: 7600735. DOI: 10.3390/md18100496.


Occipito-cervical instrumentation failure after radio-chemotherapy for axis solitary plasmacytoma: a case-based update.

Visocchi M, Sturiale C, Esposito G, Maira G Eur J Orthop Surg Traumatol. 2015; 22 Suppl 1:45-51.

PMID: 26662747 DOI: 10.1007/s00590-011-0930-7.


The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.

Armstrong T, Ying Y, Wu J, Acquaye A, Vera-Bolanos E, Gilbert M Neuro Oncol. 2015; 17(8):1114-20.

PMID: 25862766 PMC: 4490874. DOI: 10.1093/neuonc/nov054.


Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid D, Devogelaer J, Saag K, Lau C, Reginster J Osteoporos Int. 2011; 23(3):1083-90.

PMID: 21975559 DOI: 10.1007/s00198-011-1800-1.


Corticosteroid-use in primary and secondary brain tumour patients: a review.

Ryan R, Booth S, Price S J Neurooncol. 2011; 106(3):449-59.

PMID: 21971734 DOI: 10.1007/s11060-011-0713-3.